美亚光电：短期业绩承压，静待医疗设备新品放量

Investment Rating - The report maintains an "Accumulate" rating for the company [2][3]. Core Views - The company is experiencing short-term performance pressure, with a focus on the upcoming release of new medical equipment [2]. - The revenue for the first three quarters of 2024 is reported at 1.578 billion yuan, a decrease of 4.78% year-on-year, while the net profit attributable to shareholders is 450 million yuan, down 20.09% year-on-year [2]. - The sales volume of CBCT has surpassed 20,000 units, indicating potential stabilization in the industry [2]. - New medical equipment products are expected to create new growth points for the company [2]. Financial Performance Summary - For 2024-2026, the projected revenues are 2.283 billion, 2.529 billion, and 2.780 billion yuan, with year-on-year growth rates of -5.87%, 10.79%, and 9.90% respectively [3]. - The net profit attributable to shareholders is forecasted to be 637 million, 708 million, and 788 million yuan for the same period, with growth rates of -14.52%, 11.14%, and 11.32% respectively [3]. - The company's PE ratios for 2024-2026 are projected to be 22.31, 20.07, and 18.03 times [3].